Collegium Pharmaceutical Stock Performance
| COLL Stock | USD 45.79 0.51 1.13% |
Collegium Pharmaceutical has a performance score of 1 on a scale of 0 to 100. The firm shows a Beta (market volatility) of 0.69, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Collegium Pharmaceutical's returns are expected to increase less than the market. However, during the bear market, the loss of holding Collegium Pharmaceutical is expected to be smaller as well. Collegium Pharmaceutical right now shows a risk of 2.1%. Please confirm Collegium Pharmaceutical downside variance, and the relationship between the sortino ratio and accumulation distribution , to decide if Collegium Pharmaceutical will be following its price patterns.
Risk-Adjusted Performance
Weak
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Collegium Pharmaceutical are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. Despite quite persistent essential indicators, Collegium Pharmaceutical is not utilizing all of its potentials. The latest stock price mess, may contribute to short-term losses for the institutional investors. ...more
Actual Historical Performance (%)
One Day Return 1.13 | Five Day Return (3.27) | Year To Date Return 0.57 | Ten Year Return 137.87 | All Time Return 272.58 |
1 | Disposition of 17600 shares by Scott Dreyer of Collegium Pharmaceutical at 15.9 subject to Rule 16b-3 | 12/08/2025 |
2 | Best Value Stocks to Buy for Dec. 18 | 12/18/2025 |
3 | Corcept Surges 9.8 percent Is This an Indication of Further Gains | 01/05/2026 |
4 | Collegium Provides 2026 Financial Guidance and Business Update | 01/08/2026 |
5 | Collegium Pharmaceutical Stock Price Down 6.8 percent After Analyst Downgrade | 01/09/2026 |
6 | Collegium Pharmaceutical EVP Sells COLL 17,600 Shares Amid Strong Close of 2025 | 01/14/2026 |
7 | Is It Too Late To Consider Collegium Pharmaceutical After A 40 percent One Year Gain | 01/16/2026 |
8 | 1 Profitable Stock on Our Watchlist and 2 That Underwhelm | 02/09/2026 |
9 | Collegium to Report Fourth Quarter and Full-Year 2025 Financial Results on February 26, 2026 | 02/12/2026 |
| Begin Period Cash Flow | 240 M | |
| Total Cashflows From Investing Activities | -287.8 M |
Collegium | Build AI portfolio with Collegium Stock |
Collegium Pharmaceutical Relative Risk vs. Return Landscape
If you would invest 4,534 in Collegium Pharmaceutical on November 16, 2025 and sell it today you would earn a total of 45.00 from holding Collegium Pharmaceutical or generate 0.99% return on investment over 90 days. Collegium Pharmaceutical is currently generating 0.0379% in daily expected returns and assumes 2.0954% risk (volatility on return distribution) over the 90 days horizon. In different words, 18% of stocks are less volatile than Collegium, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Collegium Pharmaceutical Target Price Odds to finish over Current Price
The tendency of Collegium Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 45.79 | 90 days | 45.79 | about 76.78 |
Based on a normal probability distribution, the odds of Collegium Pharmaceutical to move above the current price in 90 days from now is about 76.78 (This Collegium Pharmaceutical probability density function shows the probability of Collegium Stock to fall within a particular range of prices over 90 days) .
Collegium Pharmaceutical Price Density |
| Price |
Predictive Modules for Collegium Pharmaceutical
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Collegium Pharmaceutical. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Collegium Pharmaceutical Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Collegium Pharmaceutical is not an exception. The market had few large corrections towards the Collegium Pharmaceutical's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Collegium Pharmaceutical, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Collegium Pharmaceutical within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.05 | |
β | Beta against Dow Jones | 0.69 | |
σ | Overall volatility | 1.49 | |
Ir | Information ratio | 0.01 |
Collegium Pharmaceutical Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Collegium Pharmaceutical for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Collegium Pharmaceutical can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Collegium Pharmaceutical currently holds 859.3 M in liabilities with Debt to Equity (D/E) ratio of 3.82, implying the company greatly relies on financing operations through barrowing. Collegium Pharmaceutical has a current ratio of 0.97, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Collegium Pharmaceutical's use of debt, we should always consider it together with its cash and equity. | |
| Over 98.0% of Collegium Pharmaceutical shares are held by institutions such as insurance companies | |
| Latest headline from globenewswire.com: Collegium to Report Fourth Quarter and Full-Year 2025 Financial Results on February 26, 2026 |
Collegium Pharmaceutical Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Collegium Stock often depends not only on the future outlook of the current and potential Collegium Pharmaceutical's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Collegium Pharmaceutical's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 40.4 M | |
| Cash And Short Term Investments | 162.8 M |
Collegium Pharmaceutical Fundamentals Growth
Collegium Stock prices reflect investors' perceptions of the future prospects and financial health of Collegium Pharmaceutical, and Collegium Pharmaceutical fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Collegium Stock performance.
| Return On Equity | 0.23 | ||||
| Return On Asset | 0.0675 | ||||
| Profit Margin | 0.08 % | ||||
| Operating Margin | 0.32 % | ||||
| Current Valuation | 1.96 B | ||||
| Shares Outstanding | 31.61 M | ||||
| Price To Earning | 28.80 X | ||||
| Price To Book | 5.21 X | ||||
| Price To Sales | 1.89 X | ||||
| Revenue | 631.45 M | ||||
| Gross Profit | 667.51 M | ||||
| EBITDA | 341.7 M | ||||
| Net Income | 69.19 M | ||||
| Cash And Equivalents | 122.72 M | ||||
| Cash Per Share | 3.60 X | ||||
| Total Debt | 859.3 M | ||||
| Debt To Equity | 3.82 % | ||||
| Current Ratio | 0.99 X | ||||
| Book Value Per Share | 8.70 X | ||||
| Cash Flow From Operations | 204.98 M | ||||
| Earnings Per Share | 1.63 X | ||||
| Market Capitalization | 1.43 B | ||||
| Total Asset | 1.66 B | ||||
| Retained Earnings | (164 M) | ||||
| Working Capital | (27.25 M) | ||||
| Current Asset | 96.88 M | ||||
| Current Liabilities | 8.43 M | ||||
About Collegium Pharmaceutical Performance
By examining Collegium Pharmaceutical's fundamental ratios, stakeholders can obtain critical insights into Collegium Pharmaceutical's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Collegium Pharmaceutical is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 58.74 | 55.80 | |
| Return On Tangible Assets | 0.10 | 0.11 | |
| Return On Capital Employed | 0.13 | 0.14 | |
| Return On Assets | 0.04 | 0.04 | |
| Return On Equity | 0.27 | 0.29 |
Things to note about Collegium Pharmaceutical performance evaluation
Checking the ongoing alerts about Collegium Pharmaceutical for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Collegium Pharmaceutical help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Collegium Pharmaceutical currently holds 859.3 M in liabilities with Debt to Equity (D/E) ratio of 3.82, implying the company greatly relies on financing operations through barrowing. Collegium Pharmaceutical has a current ratio of 0.97, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Collegium Pharmaceutical's use of debt, we should always consider it together with its cash and equity. | |
| Over 98.0% of Collegium Pharmaceutical shares are held by institutions such as insurance companies | |
| Latest headline from globenewswire.com: Collegium to Report Fourth Quarter and Full-Year 2025 Financial Results on February 26, 2026 |
- Analyzing Collegium Pharmaceutical's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Collegium Pharmaceutical's stock is overvalued or undervalued compared to its peers.
- Examining Collegium Pharmaceutical's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Collegium Pharmaceutical's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Collegium Pharmaceutical's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Collegium Pharmaceutical's stock. These opinions can provide insight into Collegium Pharmaceutical's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Collegium Pharmaceutical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For more information on how to buy Collegium Stock please use our How to buy in Collegium Stock guide.You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Collegium Pharmaceutical. Projected growth potential of Collegium fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Collegium Pharmaceutical assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth 2.132 | Earnings Share 1.63 | Revenue Per Share | Quarterly Revenue Growth 0.314 | Return On Assets |
The market value of Collegium Pharmaceutical is measured differently than its book value, which is the value of Collegium that is recorded on the company's balance sheet. Investors also form their own opinion of Collegium Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Collegium Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Collegium Pharmaceutical's market value can be influenced by many factors that don't directly affect Collegium Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Collegium Pharmaceutical's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Collegium Pharmaceutical should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Collegium Pharmaceutical's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.